– Achieves development milestones required to complete Series A financing – – Plans to file Phase 2 investigational new drug

– Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes – –

Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01 – Second grants from GlycoNet and

Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes – ZT-01

Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01 – Proof-of-Concept Trial to Evaluate the Effect of ZT-01

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 –

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly

Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the

Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials

Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a